Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01069627
PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peginterferon alfa-2a [Pegasys]Drug: Peginterferon alfa-2b [PegIntron®]
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1656
- Registration Number
- NCT01066819
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
Phase 4
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT01066884
A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia
Phase 4
Terminated
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT01066000
- Locations
- 🇮🇩
Advent Hospital; Kidney and Hipertension, Bandung, Indonesia
🇮🇩Sanglah Hospital; Kidney and Hipertension, Denpasar, Indonesia
🇮🇩Rumah Sakit Pgi Cikini; Renal & Hypertension, Jakarta, Indonesia
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peginterferon alfa-2a [Pegasys]Drug: Peginterferon alfa-2b [PegIntron®]
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2343
- Registration Number
- NCT01066793
PRM-151 in the Prevention of Scarring Following Trabeculectomy
Phase 2
Completed
- Conditions
- Glaucoma
- Interventions
- Drug: PRM-151Drug: Placebo
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 124
- Registration Number
- NCT01064817
- Locations
- 🇳🇱
UMC St. Radboud West, Nijmegen, Netherlands
🇬🇧Oxford Eye Hosiptal, Oxford, United Kingdom
🇬🇧St. Thomas, London, United Kingdom
A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 107
- Registration Number
- NCT01063062
- Locations
- 🇪🇬
Banha Educational Hospital; Rheumatology, Banha, Egypt
🇪🇬Kasr El Ainy Hospital; Rheumatology, Cairo, Egypt
🇪🇬Manial Specialized Hospital; Rheumatology, Cairo, Egypt
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 936
- Registration Number
- NCT01059682
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 168
- Registration Number
- NCT01057667
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
Phase 4
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 357
- Registration Number
- NCT01056510
© Copyright 2025. All Rights Reserved by MedPath